function getval(val){
 var a1=val.replace(/<\/?.+?>/g,"");
 var a2=a1.replace(/ /g,"");
 return a2;
}
//document.write('http://wxzl.cogonline.com/html/CeShiZhuanLanYi/WenZhang/YiShiBaoDao/568.html');
wx.config({
debug:  false, 
appId: 'wx85d01b1d7184c45d',
timestamp: 1714296085,
nonceStr: 'z8m3qRL1qISQ99Ha',
signature: 'adae8d784c892db57b40702e894e516c2c6d6f6c',
jsApiList: [ 
   'checkJsApi', 
   'onMenuShareTimeline', 
   'onMenuShareAppMessage', 
   'onMenuShareQQ', 
   'onMenuShareWeibo'
]
});
wx.ready(function () { 
	wx.onMenuShareTimeline({  
	title: '有望突破桎梏! PARP抑制剂尼拉帕利双靶联合向铂耐药复发性卵巢癌发起挑战', 
	link: 'http://wxzl.cogonline.com/html/CeShiZhuanLanYi/WenZhang/YiShiBaoDao/568.html',
	imgUrl: 'http://wxzl.cogonline.com/wp/logo.jpg',
	success: function () {
		//alert('fx-ok');
	},
	cancel: function () {
		//alert('fx-no');
	}
	});
	wx.onMenuShareAppMessage({  
		title: '有望突破桎梏! PARP抑制剂尼拉帕利双靶联合向铂耐药复发性卵巢癌发起挑战', 
		link: 'http://wxzl.cogonline.com/html/CeShiZhuanLanYi/WenZhang/YiShiBaoDao/568.html',
		imgUrl: 'http://wxzl.cogonline.com/wp/logo.jpg',
		desc: getval(''),
		success: function () {
			//alert('fx-ok');
		},
		cancel: function () {
			//alert('fx-no');
		}
	});
});	
wx.error(function (res) {
	//alert(location.href.split('#')[0]);
	//alert('err:'+res.errMsg);  
});
if(location.href.indexOf("?") >= 1 ){
	location.href=location.href.substring(0,location.href.indexOf("?"));
}